Effect of D-alanylation of (lipo)teichoic acids of Staphylococcus aureus on host secretory phospholipase A2 action before and after phagocytosis by human neutrophils

Journal of Immunology

Volumn 176, Issue 8, 2006, Pages 4987-4994

  Hunt, Catherine L ^a,b   Nauseef, William M ^a,b   Weiss, Jerrold P ^a,b,c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c Inflammation Program   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEXTRO ALANINE; GROUP IIA PHOSPHOLIPASE A2; GROUP V PHOSPHOLIPASE A2; GROUP X PHOSPHOLIPASE A2; LIPOTEICHOIC ACID; PHOSPHOLIPASE A2; UNCLASSIFIED DRUG;

ALANYLATION; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; CHEMICAL MODIFICATION; CONTROLLED STUDY; CYTOTOXICITY; DLT GENE; DLTA GENE; ENZYME ACTIVATION; ENZYME ACTIVITY; EXUDATE; GENE; HUMAN; HUMAN CELL; INFLAMMATION; NEUTROPHIL; NEUTROPHIL GRANULE; NONHUMAN; OPERON; PHAGOCYTOSIS; PHOSPHOLIPID METABOLISM; PRIORITY JOURNAL; SERUM; STAPHYLOCOCCUS AUREUS;

EID: 33645786299     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.176.8.4987     Document Type: Article

References (46)

1. von Eiff, C., K. Becker, K. Machka, H. Stammer, and G. Peters. 2001. Nasal carriage as a source of Staphylococcus aureus bacteremia. N. Engl. J. Med. 344: 11-16.
2. Peacock, S. J., I. de Silva, and F. D. Lowy. 2001. What determines nasal carriage of Staphylococcus aureus? Trends Microbiol. 9: 605-610.
3. Lowy, F. D. 1998. Staphylococcus aureus infections. N. Engl. J. Med. 339: 520-532.
4. Weinrauch, Y., C. Abad, N. Liang, S. F. Lowry, and J. Weiss. 1998. Mobilization of potent plasma bactericidal activity during systemic bacterial challenge. J. Clin. Invest. 102: 633-638.
5. Kobayashi, S. D., J. M. Voyich, and F. R. DeLeo. 2003. Regulation of the neutrophil-mediated inflammatory response to infection. Microbes Infect. 5: 1337-1344.
6. Elsbach, P., and J. Weiss. 1988. Phagocytosis of bacteria and phospholipid degradation. Biochim. Biophys. Acta 947: 29-52.
7. Fournier, B., and D. J. Philpott. 2005. Recognition of Staphylococcus aureus by the innate immune system. Clin. Microbiol. 18: 521-540.
8. Lekstrom-Himes, J. A., and J. I. Gallin. 2000. Immunodeficiency diseases caused by defects in phagocytes. N. Engl. J. Med. 343: 1703-1714.
9. Molne, L., M. Verdrengh, and A. Tarkowski. 2000. Role of neutrophil leukocytes in cutaneous infection caused by Staphylococcus aureus. Infect. Immun. 68: 6162-6167.
10. Lee, W. L., R. E. Harrison, and S. Grinstein. 2003. Phagocytosis by neutrophils. Microb. Infect. 5: 1299-1306.
11. Roos, D., R. van Bruggen, and C. Meischl. 2003. Oxidative killing of microbes by neutrophils. Microb. Infect. 5: 1307-1315.
12. Hampton, M. B., A. J. Kettle, and C. C. Winterbourn. 1998. Inside the neutrophil phagosome: oxidants, myeloperoxidase, and bacterial killing. Blood 92: 3007-3017.
13. 2 and phagocyte NADPH oxidase in digestion of phospholipids of Staphylococcus aureus ingested by human neutrophils. J. Immunol. 175: 4653-4661.
14. Gresham, H. D., J. H. Lowrance, T. E. Caver, B. S. Wilson, A. L. Cheung, and F. P. Lindberg. 2000. Survival of Staphylococcus aureus inside neutrophils contributes to infection. J. Immunol. 164: 3713-3722.
15. Voyich, J. M., K. R. Braughton, D. E. Sturdevant, A. R. Whitney, B. Said-Salim, S. F. Porcella, R. D. Long, D. W. Dorward, D. J. Gardner, B. N. Kreiswirth, et al. 2005. Insights into mechanisms used by Staphylococcus aureus to avoid destruction by human neutrophils. J. Immunol. 175: 3907-3919.
16. 2 against Staphylococcus aureus. J. Immunol. 162: 7402-7408.
17. 2 is the principal bactericide for staphylococci and other Gram-positive bacteria in human tears. Infect. Immun. 66: 2791-2797.
18. 2. J. Clin. Invest. 97: 250-257.
19. 2 in serum of patients with bacterial infections. J. Infect. Dis. 185: 1767-1772.
20. 2s in human neutrophils: role in eicosanoid production and Gram-negative bacterial phospholipid hydrolysis. J. Biol. Chem. 277: 5061-5073.
21. 2 enzymes: classification and characterization. Biochim. Biophys. Acta 1488: 1-19.
22. 2. J. Biol. Chem. 277: 5849-5857.
23. 2: a major physiological role for the group IIA enzyme that depends on the very high pI of the enzyme to allow penetration of the bacterial cell wall. J. Biol. Chem. 277: 1788-1793.
24. 2 against Staphylococcus aureus. J. Biol. Chem. 277: 47636-47644.
25. Peschel, A. 2002. How do bacteria resist human antimicrobial peptides? Trends Microbiol. 10: 179-186.
26. Collins, L. V., S. A. Kristian, C. Weidenmaier, M. Faigle, K. P. M. van Kessel, J. A. G. van Strijp, F. Gotz, B. Neumeister, and A. Peschel. 2002. Staphylococcus aureus strains lacking D-alanine modifications of teichoic acids are highly susceptible to human neutrophil killing and are virulence attenuated in mice. J. Infect. Dis. 186: 214-219.
27. Peschel, A., C. Vuong, M. Otto, and F. Gotz. 2000. The D-alanine residues of Staphylococcus aureus teichoic acids alter the susceptibility to vancomycin and the activity of autolytic enzymes. Antimicrob. Agents Chemother. 44: 2845-2847.
28. Peschel, A., M. Otto, R. W. Jack, H. Kalbacher, G. Jung, and F. Gotz. 1999. Inactivation of the dlt operon in Staphylococcus aureus confers sensitivity to defensins, protegrins, and other antimicrobial peptides. J. Biol. Chem. 274: 8405-8410.
29. Gross, M., S. E. Cramton, F. Gotz, and A. Peschel. 2001. Key role of teichoic acid net charge in Staphylococcus aureus colonization of artificial surfaces. Infect. Immun. 69: 3423-3426.
30. Boyum, A. 1968. Isolation of mononuclear cells and granulocytes from human blood: isolation of mononuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g. Scand. J. Clin. Lab. Invest. 97(Suppl.): 77-89.
31. Elabach, P., and J. Weiss. 1991. Utilization of labeled Escherichia coli as phospholipase substrate. Methods Enzymol. 197: 24-31.
32. 2. Infect. Immun. 68: 1259-1264.
33. Verbrugh, H. A., P. K. Peterson, B. Y. Nguyen, S. P. Sisson, and Y. Kim. 1982. Opsonization of encapsulated Staphylococcus aureus: the role of specific antibody and complement. J. Immunol. 129: 1681-1687.
34. Cunnion, K. M., H. M. Zhang, and M. M. Frank. 2003. Availability of complement bound to Staphylococcus aureus to interact with membrane complement receptors influences efficiency of phagocytosis. Infect. Immun. 71: 656-662.
35. 2 against Gram-positive bacteria. J. Clin. Invest. 103: 715-721.
36. Short, S. A., and D. C. White. 1972. Biosynthesis of cardiolipin from phosphatidylglycerol in Staphylococcus aureus. J. Bacteriol. 109: 820-826.
37. Clements, M. O., and S. J. Foster. 1999. Stress resistance in Staphylococcus aureus. Trends Microbiol. 7: 458-462.
38. 2 against experimental anthrax. J. Immunol. 175: 6786-6791.
39. Weiss, J., A. S. Bayer, and M. Yeaman. 2006. Cellular and extracellular defenses against staphylococcal infections. In Gram-Positive Pathogens, 2nd Ed. V. A. Fischetti, R. P. Novick, J. J. Ferretti, D. A. Portnoy, and J. I. Rood, eds. ASM Press, Washington, D.C., pp. 431-441.
40. 2 in inflammatory diseases and trauma. Biochim. Biophys. Acta 1488: 83-90.
41. 2α. Prostaglandins Other Lipid Mediat. 75: 79-89.
42. 2s. J. Biol. Chem. 275: 5785-5793.
43. 2 expression in alveolar macrophages. FEBS Lett. 579: 4923-4927.
44. 2-IIA expression in alveolar macrophages through NF-κB and PPAR-γ-dependent pathways. Mol. Pharmacol. 61: 786-794.
45. 2 types in human airway epithelial cells induced by tumor necrosis factor-α and IFN-γ. J. Interferon Cytokine Res. 22: 947-955.
46. Neuhaus, F. C., and J. Baddiley. 2003. A continuum of anionic charge: structures and functions of D-alanyl-teichoic acids in Gram-positive bacteria. Microbiol. Mol. Biol. Rev. 67: 686-723.